A Prospective Randomized Phase II Study to Identify Predictive Biomarkers and Mechanisms of Therapy Resistance in Patients With HER2-negative Metastatic Breast Cancer Treated With the Combination of Bevacizumab and Paclitaxel (BEVPAC).

Trial Profile

A Prospective Randomized Phase II Study to Identify Predictive Biomarkers and Mechanisms of Therapy Resistance in Patients With HER2-negative Metastatic Breast Cancer Treated With the Combination of Bevacizumab and Paclitaxel (BEVPAC).

Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Aug 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Paclitaxel (Primary)
  • Indications Advanced breast cancer
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Acronyms BEVPAC
  • Most Recent Events

    • 16 Aug 2017 Planned primary completion date changed from 1 May 2017 to 1 May 2018.
    • 10 Jun 2017 Biomarkers information updated
    • 22 Feb 2016 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top